WO2020187660A1 - System comprising a pre-fillable syringe and a package for the pre-fillable syringe - Google Patents
System comprising a pre-fillable syringe and a package for the pre-fillable syringe Download PDFInfo
- Publication number
- WO2020187660A1 WO2020187660A1 PCT/EP2020/056480 EP2020056480W WO2020187660A1 WO 2020187660 A1 WO2020187660 A1 WO 2020187660A1 EP 2020056480 W EP2020056480 W EP 2020056480W WO 2020187660 A1 WO2020187660 A1 WO 2020187660A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- syringe
- package
- cap
- replacement cap
- fillable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/002—Packages specially adapted therefor, e.g. for syringes or needles, kits for diabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/20—Closure caps or plugs for connectors or open ends of tubes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/28—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/3129—Syringe barrels
- A61M5/3134—Syringe barrels characterised by constructional features of the distal end, i.e. end closest to the tip of the needle cannula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
- A61M5/321—Means for protection against accidental injuries by used needles
- A61M5/3213—Caps placed axially onto the needle, e.g. equipped with finger protection guards
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M2005/3103—Leak prevention means for distal end of syringes, i.e. syringe end for mounting a needle
- A61M2005/3104—Caps for syringes without needle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M2005/3117—Means preventing contamination of the medicament compartment of a syringe
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2209/00—Ancillary equipment
- A61M2209/08—Supports for equipment
- A61M2209/084—Supporting bases, stands for equipment
Definitions
- the invention relates to a package suitable and intended for receiving a pre-fillable syringe comprising a syringe barrel and a syringe tip, wherein the syringe tip is provided with a tip cap.
- the invention also relates to a system and the use of the system comprising a pre-fillable syringe with a syringe barrel and a syringe tip and a package suitable and intended for receiving the pre-fillable syringe, wherein the syringe tip is provided with a tip cap. Further, the invention relates to a replacement cap for a pre-fillable syringe.
- Pre-fillable syringes can be used as a kit together with the medium to be administered or delivered to the user, where the pre-fillable syringes of the kit are filled with the medium.
- pre-filled syringes have emerged as one of the fastest- growing choices for unit dose medication.
- the handling of such syringes is easy because the medium to administer does not need to be transferred to the syringe before the usage.
- the usage of pre-filled syringes minimizes drug waste and increases product life span.
- pre-filled syringes are a convenient choice.
- modem vaccines react very sensibly to outer influence factors and are therefore securely stored in a pre-filled syringe.
- Pre-fillable syringe bodies comprise a syringe barrel, a syringe tip and optionally a finger flange.
- the syringe tip is already provided with a piercing means.
- a piercing means may be a needle, a canula, or a similar element.
- the syringe bodies are produced by a primary packaging producer under clean room conditions. After a sterilization, the syringe bodies are provided with a tip cap and placed in a so-called syringe nest.
- the tip cap usually is placed on the syringe tip and may also enclose a needle arranged in the syringe tip.
- the pre-fillable syringe is then delivered to a pharmaceutical company which either provide a kit together with the medium to administer or, preferably, fills the syringes with the medium.
- a plunger or piston is introduced in the syringe barrel, by which the barrel is closed on its proximal side.
- the filled syringe is then placed in a secondary packaging.
- the tip cap can seal the tip and optionally the needle.
- the tip caps are at least partially made of an elastic material. Due to the limited space for a syringe in the syringe nest, the tip caps are usually designed as small as possible. Such small sized tip caps may be, however, inconvenient for the user to handle.
- the user needs to set the dosage before the actual administration of the medium, which may be done at a later point.
- the tip cap may need to be temporally removed.
- the reclosing of the syringe with the tip cap may result in an unwanted introduction of a portion of air in the syringe barrel. Such a portion of air may cause irritations to the patient.
- the medium in the syringe barrel is a higher- viscosity medium, the enclosed portion of air may be difficult to remove.
- WO 2018/038078 A1 discloses a medical equipment package with a plurality of syringe packaging bodies including a prefilled syringe system and a packaging main body, and an outer box which accommodates a plurality of syringe packaging bodies.
- a needle unit of the prefilled syringe system is supported with respect to a needle unit case with a largest outer diameter portion provided at a tip end of a needle hub engaging with an inner surface of the needle unit case.
- a plurality of syringe packaging bodies is arranged such that an axial direction of a needle body is in an up-and-down direction of the outer box.
- the prefilled syringe is sealed with a sealing cap, however no replacement cap is provided.
- An object of the invention is therefore to provide a pre-fillable syringe, package for receiving a pre-fillable syringe, and a system comprising a pre-fillable syringe and a package that overcomes the above-mentioned disadvantages.
- the invention is also directed to the system of the invention, wherein the syringe is pre-filled with a ready-to-use pharmaceutical formulation.
- the invention is directed to a kit comprising the system of the invention together with a pharmaceutical formulation in the form of either a ready-to-use aqueous solution or a powder to be reconstituted in a suitable vehicle, and instructions to administer said pharmaceutical formulation.
- Fig. 1 shows a pre-fillable syringe without a tip cap
- Fig. 2a shows a pre-fillable syringe with a tip cap
- Fig. 2b shows a replacement cap
- Fig. 3 shows a pre-fillable syringe with a replacement cap
- Fig. 4 shows a pre-fillable syringe with a replacement cap on a support surface
- Fig. 5a shows a pre-fillable syringe with a tip cap, as in Fig. 2a;
- Fig. 5b shows a replacement cap as in Fig. 2b, with different foot portion
- Fig. 6 shows a package body according to one embodiment without a pre-fillable syringe
- Fig. 7 shows a package body according to one embodiment with a pre-fillable syringe and a replacement cap
- Fig. 8 shows a package body according to one embodiment with a pre-fillable syringe placed in a replacement cap
- Fig. 9 shows a bottom perspective view of a plunger according to one or more embodiments
- Fig. 10 shows a top perspective view of the plunger
- Fig. 11 shows a bottom plan view of the plunger
- Fig. 12 shows a top plan view of the plunger
- Fig. 13 shows a side view of the plunger.
- a system comprising a pre-fillable syringe with a syringe barrel and a syringe tip and a package suitable and intended for receiving the pre-fillable syringe, wherein the syringe tip is provided with a tip cap, wherein the system comprises a replacement cap for the pre-fillable syringe, and wherein the package is suitable and intended for receiving the replacement cap.
- the system has the advantage that a package, presented to the user, comprises the pre-fillable syringe to use and a suitable replacement cap.
- the user may retrieve the pre-fillable syringe from the package, remove the tip cap and optionally set the dosage of the pre-fillable syringe.
- the replacement cap is already available to the user and does not need to be obtained otherwise. Further, the replacement cap does not need to be retrieved from an additional package. For such a retrieval of the replacement cap from the additional package, the user needs to put the possibly already open syringe down. Putting down the pre-fillable syringe could contaminate the syringe tip and implies an unnecessary complicated handling.
- the system according to this invention provides the user the pre- fillable syringe and the replacement cap in one package.
- the replacement cap is therefore always available with the pre-fillable syringe and does not need to be obtained at a time, when the tip cap is possibly already removed.
- the mounting of the replacement cap may therefore be performed in an uncomplicated manner.
- the further use of a replacement cap also has the advantage that the handling of the syringe is easier for the user, since it may be difficult to grasp and remove the comparatively small tip cap.
- distal and proximal are understood such that a distal end of a syringe is closer to the application site as the proximal end.
- distal direction and“proximal directed” are understood analogously.
- the longitudinal axis (X), horizontal axis (Y), and vertical axis (Z) are used in relation to the package body.
- the longitudinal axis (X’), horizontal axis (Y’), and vertical axis (Z’) are used in relation to the pre-fillable syringe.
- the longitudinal axis (X”), horizontal axis (Y”), and vertical axis (Z”) are used in relation to the replacement cap.
- the package comprises a package body forming a first cavity defined by a sidewall and a bottom wall.
- the pre-fillable syringe is arrangeable in said first cavity.
- the package body extends along a longitudinal axis (X), a horizontal axis (Y) and a vertical axis (Z), which are perpendicular to each other.
- At least one second receiving element is provided in the first cavity of the package body, in which the syringe barrel is receivable.
- Preferably two second receiving elements are provided in the first cavity of the package body.
- the at least one second receiving element is arranged on the bottom wall.
- the at least one second receiving element comprises a semicircular top section, arranged on a base section.
- the semicircular top section extends preferably along the horizontal axis (Y) and the longitudinal axis (X) and is open in the vertical axis (Z). Further, the semicircular top section is suitable and intended for receiving the syringe barrel.
- the semicircular top section comprises two arms which encompass the syringe barrel at least in part.
- a distal end of the syringe barrel is supported by a first of the second receiving elements and a proximal end of the syringe barrel is supported by a second of the second receiving elements.
- a first of the second receiving elements is located close to or at the region where the syringe barrel merges into the syringe tip.
- the second of the second receiving elements is located close to the finger flange of the syringe arranged in the package body.
- the first and the second of the second receiving elements are separated along the longitudinal axis (X’) of the pre-fillable syringe.
- a central axis of the pre-fillable syringe extends preferably parallel to the bottom wall of the package body.
- the central axis extends in a height L2 above the bottom wall. The height L2 is dimensioned such that an easy grasping of the pre-fillable syringe is possible.
- At least one third receiving element is provided in the first cavity of the package body, in which a rod of the pre-fillable syringe is receivable.
- the third receiving element comprises two walls extending along the vertical axis (Z), forming a cavity in which the rod is received.
- said walls extend along the longitudinal axis (X).
- the at least one third receiving element has a bottom wall which is formed semi circularly and connects said walls with each other.
- a gap between the second of the second receiving elements and the third receiving element is provided.
- a finger flange of the pre-fillable syringe projects through said gap such that the finger flange is sandwiched between second of the second receiving elements and the third receiving element.
- the finger flange of the pre-fillable syringe may preferably project, when the syringe is placed inside the package body. Since the finger flange is preferably sandwiched between the second of the second receiving elements and the third receiving element the pre-fillable syringe is fasted in the package body due to an engagement of the finger flange with the second of the second receiving elements and the third receiving element.
- the length of said walls is essentially determined by the length of a section of the rod, which projects from the syringe barrel, without the length of the rod in said gap between the second of the second receiving elements and the third receiving element.
- the pre-fillable syringe further comprises a plunger or a piston connected to a rod projecting out of the syringe barrel.
- the pre-fillable syringe comprises also a finger flange.
- the finger flange may be formed on the syringe barrel. It is also conceivable that a separate finger flange element is connected to the syringe barrel, which provides a larger gripping surface.
- the syringe tip is preferably formed as a cone.
- the syringe tip has a Luer-Cone. Currently, ISO 80369 governs the Luer standards.
- the syringe tip may preferably also be equipped with a piercing means, which may be a needle, a canula, or a similar means.
- the syringe can be used without piercing means on the tip to avoid accidental harm to their mouth.
- the pre-fillable syringe is advantageously provided with a tip cap, which is arranged on the syringe tip.
- the tip cap may consist at least in part of an elastomeric material.
- the pre-fillable syringe may consist of glass or plastics.
- the replacement cap is arranged in the package, such that the replacement cap or an opening of the replacement cap is oriented along a vertical axis (Z) of the package body.
- an opening area of the replacement cap is oriented parallel to the bottom wall of the package body.
- the replacement cap comprises an inner cap for an engagement with the syringe tip.
- the replacement cap comprises an outer collar engaging with the syringe barrel for mounting the replacement cap on the syringe barrel. Further, it is favorable that the replacement cap comprises a foot portion.
- the inner cap is preferably arranged on the foot portion of the replacement cap.
- the inner cap may consist at least partially of an elastomeric material, such that a sealing connection with the syringe tip is possible.
- the syringe tip may preferably be introduced in the inner cap through an opening of the inner cap.
- the outer collar is advantageously formed as a ring which is arranged along a longitudinal axis (X”) above the opening of the inner cap.
- the ring is preferably supported by struts which are arranged at the foot portion and surround the inner cap radially.
- the three struts are placed along the circumference of the ring with an equal distance to each other. The struts project from the ring radially inward and abut at the syringe barrel, when the replacement cap is placed on the pre-fillable syringe.
- the opening area of the replacement cap is defined by the ring and the opening of the inner cap, which is placed along the longitudinal axis (X”) underneath the opening of the ring.
- the opening of the ring and the opening are advantageously parallel to each other and share the same central axis.
- the opening area of the replacement cap is defined by the ring.
- the opening area of the replacement cap, which is preferably defined by the ring, and an opening area of the inner cap are preferably oriented parallel to the bottom wall of the package body.
- a first receiving element is provided in the first cavity of the package body.
- the replacement cap is received in the first receiving element.
- the foot portion of the replacement cap is received in the first receiving element. The replacement cap is therefore placed upright in the package.
- the opening area of the replacement cap is defined by the ring and an opening area of the inner cap are preferably oriented parallel to the bottom wall of the package body.
- the foot portion is suitable to provide a stable upright positioning of the pre-fillable syringe with the replacement cap on a support surface.
- the foot portion comprises a bearing area which contacts the support surface.
- the bearing area comprises an edge, which surrounds a center axis of the replacement cap at an edge-distance.
- an upright positioning represents a very handy, practical way to place the pre-fillable syringe after removing it from the package.
- a positioning of the distal end of the pre-fillable syringe on a supporting surface is understood.
- Such a positioning bears the advantage that the proximal end is equipped with the finger flange and the rod is easy to grasp.
- a pre-fillable syringe typically has an extension which is by far larger along the longitudinal axis (X’) than along the horizontal axis (Y’).
- a stable positioning is possible as long as the center of gravity is within an area defined by a tilting edge of the bearing area.
- the bearing area may stretch over a part of a distal end face of the replacement cap, which constitutes the distal end of the foot portion. It is also conceivable that the bearing area stretches over the entire distal end face. Further, it is conceivable that the bearing area stretches along the edge of the distal end face. A displacement of the center of gravity in a radial direction may not affect the stability of the standing, as long as the center of gravity is not further radially outwards placed than the tilting edge.
- the center of gravity is closer to the proximal end of the syringe. This means that a small displacement of the center of gravity can cause the upright standing syringe to topple.
- the edge-distance between the edge of the bearing area and the center axis is at least twice the radius of the syringe barrel, more preferably, the edge-distance is at least three times the radius of the syringe barrel. Preferably, the edge-distance is at least four times the radius of the syringe barrel. Preferably, the edge-distance is at least five times the radius of the syringe barrel. Due to such an embodiment, the tilting edge is further away from the center axis. Thus, a larger displacement of the center of gravity is possible, before the upright standing syringe topples. Hence, the standing stability is enhanced.
- the distal end face of the foot portion comprises an edge, surrounding a center axis of the replacement cap at a certain distance.
- This edge may preferably be parallel to the edge of the bearing area, which is considered as a tilting edge.
- the edge of the distal end face defines the shape of the foot section, which can be arbitrary.
- the foot portion has a disc-like shape.
- the foot portion is essentially circular.
- the foot portion can be rectangular.
- the syringe After the described equipping of the syringe with a replacement cap, which may be done only one-handed, due to the preferable placement and orientation of the replacement cap in the package, the syringe may be placed standing upright and is easily accessible for the user, when needed.
- the bearing area and/or the edge surrounding the bearing face is/are coated at least partially with a rubberized material.
- a rubberized material Such an embodiment bears the advantage that slipping of the foot portion on the supporting surface is inhibited or minimized.
- the foot portion is designed as a suction cup.
- a suction cup is a device or object that uses the negative fluid pressure of air to adhere to nonporous surfaces, creating a partial vacuum.
- the working face of the foot portion is preferably made of elastic, flexible material and has a curved surface. When the center of the foot portion is pressed against a flat supporting surface, the volume of the space between the foot portion and the flat surface is reduced. Thus, the air or water between the foot portion and the surface is to be expelled past the edge of the cup. By this, a lack of pressure develops between the foot portion and the supporting surface. The pressure difference between the atmosphere on the outside of the foot portion and the low-pressure between the foot portion and the supporting surface keeps the foot portion adhered to the surface.
- the replacement cap is produced by injection molding, preferably by multi-component injection molding.
- the sidewall of the package body extends essentially along a vertical axis (Z).
- a angle to the vertical axis (Z).
- Such an angle could be in a range between 0° to 25°, preferably 0° to f 0°, preferably 0° to 5°.
- the sidewall of the package body is provided with a flange on its upper end, wherein the flange extends outwards essentially along the longitudinal (X) or the horizontal (Y) axis.
- the flange surrounds the package body.
- the package comprises a closure element, which covers the package body at least in part.
- the closure element covers the package body entirely.
- the closure element is arranged on the flange, provided on the side walls.
- the closure element could be a foil or a dimensionally stable element.
- the closure element could preferably be connected to the flange by a clamping connection, a snap connection, a welded connection or an adhesion bond, or similar connections.
- a connection is torn off, preferably before the usage in order to expose the pre-fillable syringe in the package body.
- the closure element is slidably arranged on the package body.
- the closure element is slidable along a slide direction, which is preferably oriented along the longitudinal direction (X).
- the closure element is provided with a guidance element, which extends along the slide direction, in particular the longitudinal direction (X) on each edge, extending in the direction of the closure element.
- each flange of the two sidewalls extending in the slide direction, in particular the longitudinal direction is received in a guidance element.
- the package may consist of plastic.
- the package is produced in an injection molding process, preferably in a multi-component injection molding process.
- the object is also addressed by a package suitable and intended for receiving a pre-fillable syringe comprising a syringe barrel and a syringe tip, wherein the syringe tip is provided with a tip cap, wherein the package is suitable and intended for receiving a replacement cap for the pre-fillable syringe.
- the package may comprise the single features or combinations of the features described above for the system.
- the system may comprise the single features or combinations of the features described for the package. Further, the same advantages may apply for the package as described above for the system.
- the package comprises a package body, forming a first cavity defined by a sidewall and a bottom wall.
- the pre-fillable syringe is arranged in said first cavity.
- at least one second receiving element is provided in the first cavity of the package body, in which the syringe barrel is received.
- a distal end of the syringe barrel may be supported by a first of the second receiving elements and a proximal end of the syringe barrel may be supported by a second of the second receiving elements.
- a first of the second receiving elements may be located close to or at the region where the syringe barrel merges into the syringe tip.
- the second of the second receiving elements may be located close to the finger flange of the syringe arranged in the package body.
- the first and the second of the second receiving elements are separated along the longitudinal axis (X’) of the pre-fillable syringe.
- a central axis of the pre-fillable syringe extends preferably parallel to the bottom wall of the package body.
- the central axis extends in a height L2 above the bottom wall of the package body.
- a first receiving element is provided in the first cavity of the package body.
- the replacement cap is received in the first receiving element, such that the replacement cap is oriented along a vertical axis (Z) of the package body and an opening area of the replacement cap is oriented parallel to the bottom wall of the package body.
- the foot portion of the replacement cap is received in the first receiving element.
- a bearing area of the replacement cap contacts the bottom wall of the package body.
- a replacement cap for a pre-fillable syringe wherein the replacement cap comprises an inner cap for an engagement with the syringe tip, an outer collar engaging with the syringe barrel for mounting the replacement cap on the syringe barrel and a foot portion replacement cap comprising a foot portion, which is suitable to provide a stable upright positioning of the syringe with the replacement cap on a surface.
- the replacement cap may comprise the single features or combinations of the features described above for the system.
- the system may comprise the single features or combinations of the features described for the replacement cap. Further, the same advantages may apply for the replacement cap as described above for the system.
- the inner cap is preferably arranged on the foot portion of the replacement cap.
- the inner cap may consist at least partially of an elastomeric material, such that a sealing connection with the syringe tip is possible.
- the syringe tip may preferably be introduced in the inner cap through an opening of the inner cap.
- the outer collar is advantageously formed as a ring which is arranged along a vertical axis (Z’) above the opening of the inner cap.
- the ring is preferably supported by struts which are arranged at the foot portion and surround the inner cap radially.
- the three struts are placed along the circumference of the ring with an equal distance to each other. The struts project from the ring radially inward and abut at the syringe barrel, when the replacement cap is placed on the pre-fillable syringe.
- the opening area of the replacement cap is defined by the ring and the opening of the inner cap, which is placed along the vertical axis (Z) underneath the opening of the ring.
- the opening of the ring and the opening are advantageously parallel to each other and share the same central axis.
- the opening area of the replacement cap is defined by the ring.
- the opening area of the replacement cap, which is defined by the ring, and an opening area of the inner cap are preferably oriented parallel to the bottom wall of the package body.
- the foot portion is suitable to provide a stable upright positioning of the pre-fillable syringe with the replacement cap on a surface.
- an up-right positioning represents a very handy, practical way to place the syringe.
- An upright positioning can mean a positioning of the distal end on a supporting surface, such that the proximal end, equipped with the finger flange and the rod, is easy to grasp.
- the foot portion comprises an edge, surrounding a center axis of the replacement cap.
- This edge may be considered as the above-mentioned tilting edge.
- the edge defines the shape of the foot section, which can be arbitrary.
- the foot portion has a disc-like shape.
- the foot portion has a disc-like shape.
- the foot portion has an essentially circular base area.
- the foot portion has a base area which is essentially rectangular.
- the distance between the edge and the center axis is at least twice the radius of the syringe barrel, more preferably the distance between the edge and the center axis is at least three times the radius of the syringe barrel.
- the distance between the edge and the center axis is at least four times the radius of the syringe barrel.
- the distance between the edge and the center axis is at least five times the radius of the syringe barrel. Due to such an embodiment, the tilting edge is further away from the center axis. Thus, a larger displacement of the center of gravity is possible before the up-right standing syringe topples. Hence, the standing stability is enhanced.
- the syringe After the described equipping of the syringe with a replacement cap, which may be done only one-handed, due to the preferable placement and orientation of the replacement cap in the package, the syringe may be placed upright standing and is easily accessible for the user, when needed.
- the bearing area and/or the edge surrounding the bearing face is/are coated at least partially with a rubberized material.
- a rubberized material Such an embodiment bears the advantage that slipping of the foot portion on the supporting surface is inhibited.
- the foot portion is designed as a suction cup.
- a suction cup is a device or object that uses the negative fluid pressure of air to adhere to nonporous surfaces, creating a partial vacuum.
- the working face of the foot portion is preferably made of elastic, flexible material and has a curved surface. When the center of the foot portion is pressed against a flat supporting surface, the volume of the space between the foot portion and the flat surface is reduced. Thus, the air or water between the foot portion and the sur-face is to be expelled past the edge of the cup. By this, a lack of pressure develops between the foot portion and the supporting surface. The pressure difference between the atmosphere on the outside of the foot portion and the low-pressure between the foot portion and the supporting surface keeps the foot portion adhered to the surface.
- the replacement cap may consist of a plastics material.
- the replacement cap is produced by injection molding, preferably by multi-component injection molding.
- the use of the system may comprise the single features or combinations of the features described above for the system or package.
- the system or the package may comprise the single features or combinations of the features described above for the use. Further, the same advantages may apply for the use of the system as described above for the system or the package.
- the use comprises the step to set the dosage of the pre-fillable syringe.
- the usage may also comprise the step of removing the closure element.
- the syringe may be placed in an upright position on a support surface after the retrieval of the syringe equipped with the replacement cap of the package.
- a foot portion of the replacement cap is suitable to provide a stable upright positioning of the pre-fillable syringe with the replacement cap on the support surface.
- a bearing area of a foot portion of the replacement cap contacts the support surface.
- the longitudinal axis (X), horizontal axis (Y), and vertical axis (Z) are used in relation to the package body (3).
- the longitudinal axis (X’), horizontal axis (Y’), and vertical axis (Z’) are used in relation to the pre-fillable syringe (100).
- the longitudinal axis (X”), the horizontal axis (Y”), and the vertical axis (Z”) are used in relation to the replacement cap (300).
- a pre-fillable syringe comprises a syringe barrel (101) and a syringe tip (102).
- the syringe barrel (101) is cylindrically shaped and open at its proximal end. At its distal end, the syringe barrel (101) merges along the distal direction (X’ 1) into the syringe tip (102).
- the syringe tip (102) may have the form of a cone.
- the syringe tip (102) is a Luer-cone.
- a piercing means in particular a needle, a canula, or a similar means, is arranged in the syringe tip (102).
- the medium to administer is stored in the syringe barrel (101).
- the syringe barrel (101) is closed with a plunger or a piston 500, such as shown in figures 9-13), which is movable in the syringe barrel (101).
- the plunger 500 can have a flat surface on the bottom 502 thereof instead of a conic section as in a standard plunger.
- the bottom flat surface 502 of the plunger 500 allows a better dose adjustment.
- the lateral wall of the plunger has annular ridges 501 for a sealing sliding within the syringe barrel 101.
- the plunger can be fully coated with silicone, Teflon, or the like, even more preferably with a film of polytetrafluoroethylene (PTFE).
- PTFE polytetrafluoroethylene
- the Break-Loose-Force (BLF) of the plunger stopper can increase while storage duration of the filled syringe.
- the Glide-Force (GF) may not see this increase while in storage. Therefore, the difference between the two (2) forces (AF) can increase over storage duration. This can lead to the following user-experience after storage: the user increases the push-force onto a plunger rod until the plunger stopper moves.
- Break- Loose-Force & Glide-Force the user may not able to stop the force quick enough to be able to set a small dose difference.
- the coating favors an easiest actuation of the device of the invention and lowest level of subvisible particulates.
- the plunger or the piston can be attached to a rod (104), which projects in the proximal direction (X’2) from the syringe barrel (101).
- a finger support (109) is arranged on the proximal end of the rod (104).
- the syringe barrel (101) is provided with a finger flange (105).
- the finger flange (105) is a clip-on-finger flange which may be clipped on a finger flange on the syringe barrel (101).
- Such clip-on-finger flanges bear the advantage of a larger area to grasp for the user.
- the pre-fillable syringe (100) is provided with a tip cap (103) which is arranged on the syringe tip (102).
- the tip cap (103) may consist at least in part of an elastomeric material.
- a replacement cap (300) is depicted.
- a pre-fillable syringe (100) is depicted, which is equipped with a replacement cap (300).
- a package (1) is shown, in which a replacement cap (300) is arranged.
- the replacement cap (300) comprises an inner cap (301) for an engagement with the syringe tip (102).
- the inner cap (301) is arranged on a foot portion (303) of the replacement cap.
- the inner cap (301) may consist at least partially of an elastomeric material, such that a sealing connection to the syringe tip (102) is possible.
- the syringe tip (102) may be introduced in the inner cap (301) through the opening (304) of the inner cap (301).
- the replacement cap (300) comprises an outer collar (302) engaging with the syringe barrel (101) for mounting the replacement cap (300) and a foot portion (303).
- the outer collar (300) comprises a ring (305) which is arranged along the longitudinal axis (X”) above the opening (304) of the inner cap (301).
- the ring (305) is supported by struts (306).
- struts (306) Preferably, three struts (306) are placed along the circumference of the ring (305) with an equal radial distance to each other.
- the struts (306) are arranged at the foot portion (303) and surround the inner cap (301) radially. Further, the struts (306) project from the ring (305) radially inward and abut at the syringe barrel (101), when the replacement cap (300) is placed on the pre-fillable syringe (100).
- the replacement cap (300) comprises an opening (309) and an opening area (309a), which is defined by the ring (305).
- the opening (304) of the inner cap (301) is placed along the longitudinal axis (X’’) underneath the ring opening (309).
- the opening area (309a) is oriented parallel to an opening area of the opening (304) of the inner cap (301).
- the pre-fillable syringe (100) is introduced first through the opening (309) and then into the opening (304) of the inner cap (301).
- the opening (309) and the opening (304) share the same center axis (307).
- a package (1) is shown, in which a replacement cap (300) is arranged.
- the opening area (309a) is then oriented parallel to the bottom wall (6) of the package body (3).
- the foot portion (303) is suitable to provide a stable upright positioning of the pre-fillable syringe (100) on a support surface (400). This is depicted in Fig. 4. Under an upright positioning a positioning of the distal end of the pre-fillable syringe (100) on a support surface (400) is understood, such that the proximal end of the pre-fillable syringe (100), which is equipped with the finger flange (105) and the rod (104), is easy to grasp.
- the foot portion (303) comprises a bearing area (311), which contacts the supporting surface (400).
- the bearing area (311) may stretch over a part of a distal end face (312) of the replacement cap (300), which constitutes the distal end of the foot portion. It is also conceivable that the bearing area (311) stretches of the entire distal end face (312). Further, it is conceivable that the bearing area (311) stretches along the edge of the distal end face (312).
- the pre-fillable syringe (100) has an extension which is by far larger along the longitudinal axis (X’) than along the horizontal axis (Y’).
- a stable positioning is possible as long as the center of gravity is within an area defined by an edge of the bearing area (311).
- a displacement of the center of gravity in a radial direction (along the horizontal axis (Y’) or the vertical axis (Z’)) may not affect the stability of the standing as long as the center of gravity is not further radially outwards placed than the tilting edge.
- the center of gravity is closer to the proximal end of the pre-fillable syringe (100). This means that a small displacement of the center of gravity causes the upright standing syringe to topple.
- the bearing area (311) comprises an edge (313) which surrounds a center axis (307) of the replacement cap (300) at an edge-distance (308).
- the edge-distance (308) is at least twice the radius (112) of the syringe barrel (101), more preferably the edge-distance (308) is at least three times the radius (112) of the syringe barrel (101).
- the edge-distance (308) is at least four times the radius (112) of the syringe barrel (101).
- the edge-distance (308) is at least five times the radius (112) of the syringe barrel (101). Due to such an embodiment, the tilting edge is further away from the center axis. It is therefore a larger displacement necessary to tip the pre-fillable syringe (100) over.
- the distal end face (312) of the foot portion (303) comprises an edge.
- the edge of the distal end face (312) and the edge (313) of the bearing area (311) are parallel to each other and adjacent.
- the replacement cap (300) has a disc-like shape which is essentially circular, except for a cut portion (314). Said edge distance (308) is therefore essentially the radius of the disc-like shaped foot portion (313).
- the cut portion (314) extends along a secant line, meaning a line that intersects the circular replacement cap on two points of the diameter, wherein the secant does not run through the center of the circular replacement cap.
- the cut portion (314) is adjacent to a sidewall (5) extending along the longitudinal axis (X).
- the foot portion (303) according an embodiment of Fig. 5b is rectangular.
- the edge-distance (308) would therefore be the distance to the edge closest to the center axis (307).
- the foot portion (303) is, due to its dimension, also a suitable grip portion for the user to grasp the replacement cap (300).
- the foot portion (303) may also be designed as a suction cup, which is a device or object that uses the negative fluid pressure of air to adhere to nonporous surfaces, creating a partial vacuum.
- a package (1) and/or a system (200) are depicted.
- the system (200) comprises a pre-fillable syringe (100) with a syringe barrel (101) and a syringe tip (102) and a package (1) suitable and intended for receiving the pre-fillable syringe (100), wherein the syringe tip (102) is provided with a tip cap (103), wherein the system (200) comprises a replacement cap (300) for the pre-fillable syringe (100), and wherein the package (1) is suitable and intended for receiving the replacement cap (300).
- the package (1) suitable and intended for receiving a pre-fillable syringe (100) comprises a syringe barrel (101) and a syringe tip (102), wherein the syringe tip (102) is provided with a tip cap (103), wherein the package (1) is suitable and intended for receiving a replacement cap (300) for the pre-fillable syringe (100).
- the package (1) comprises a package body (3), forming a first cavity (4), defined by a sidewall (5) and a bottom wall (6), wherein the pre-fillable syringe (100) is arrangeable or arranged in said first cavity (4).
- the package body (3) extends along a longitudinal axis (X), a horizontal axis (Y), and a vertical axis (Z), which are perpendicular to each other. Further, the package body (3) has a rectangular shape.
- At least one second receiving element (7, 7a, 7b) is provided in the first cavity (4) of the package body (3), in which the syringe barrel (101) is receivable.
- the embodiments shown in the figures have two second receiving elements (7, 7a, 7b), which are arranged at the bottom wall (6) of the package body (3).
- the first (7a) of the second receiving elements (7) comprise a semicircular top section (26) arranged on a base section (27).
- the semicircular top section (26) is dimensioned to receive the syringe barrel (101).
- the second (7b) of the second receiving elements (7) also comprises a semicircular top section (26) arranged on a base section (27).
- a distal end (101a) of the syringe barrel (101) is supported by a first (7a) of the second receiving elements (7), and a proximal end (101b) of the syringe barrel (101) is supported by a second (7b) of the second receiving elements (7).
- the first (7a) of the second receiving elements (7) is located close to or at the region (110), where the syringe barrel (101) merges into the syringe tip (102). Further, the second (7b) of the second receiving elements (7) is located close to the finger flange (105) of the pre-fillable syringe (100) arranged in the package body (3).
- the first cavity (4) of the package body (3) is provided with a third receiving element (8), in which the rod (104) of the pre-fillable syringe (100) is receivable or received.
- the third receiving element (8) comprises two walls (8a, 8b) extending along the vertical axis (Z), forming a cavity in which the rod (105) is receivable or received. Further, the third receiving element (8) has a bottom wall, formed semicircularly, and connecting the walls (8a, 8b).
- the third receiving element (8) ends at its proximal end in a fixture element (30), in which the finger support (109) of the rod (104) is received.
- a gap (29) is formed between the second of the second receiving elements (7, 7b) and the third receiving element (8).
- the finger flange (105) of the pre-fillable syringe (100) may project, when the pre-fillable syringe (100) is placed inside the package body (3).
- the finger flange (105) is sandwiched between the second (7b) of the second receiving elements (7) and the third receiving element (8), such that the pre-fillable syringe (100) is fastened in the package body (3).
- the third receiving element (8) stretches, after the gap (29), essentially along the length of the section of the rod (104) projecting from the syringe barrel (101).
- a central axis (111) of the pre-fillable syringe (100) extends parallel to the bottom wall (6) of the package body (3).
- the central axis (111) extends in a height L2 above the bottom wall (6) of the package body (3). The height L2 allows an easy grasping of the pre-fillable syringe (100).
- the replacement cap (300) is arranged in the package (1), such that an opening (309) of the replacement cap (300) is oriented along a vertical axis (Z) of the package body (3).
- An opening area (309a) of the replacement cap (300) is oriented parallel to the bottom wall (6) of the package body (3).
- the center axis (307) of the replacement cap (300) is parallel to the height extension of the sidewalls (5) of the package body (3).
- the side wall(s) (5) of the package body (3) surround the package body (3) along the longitudinal axis (X) and the horizontal axis (Y).
- the sidewall(s) (5) extend(s) along the vertical axis (Z) with a height L4.
- the height L4 is at least the height L2 plus the radius (112) of the syringe barrel (101).
- the upper (along the vertical axis (Z)) end of the side wall(s) (5) is provided with a flange (31).
- the flange (31) extends outwards and surrounds the package body (3) along the longitudinal axis (X) and the horizontal axis (Y), preferably without any gap.
- a closure element (15) may be arranged on the flange (31).
- the closure element is connected with a suitable connection to the flange (31).
- the closure element (15) is shown only partly in Fig. 6 and may be a foil or a slidable stable element.
- the first cavity (4) of the package body (3) is provided with a first receiving element (2), in which the replacement cap (300) is received.
- the foot portion (303) of the replacement cap (300) is received in the first receiving element (2).
- the first receiving element (2) therefore essentially is the shape of the outer perimeter of the foot portion (303). In case of the Figs. 6 to 8 this shape would be essentially circular with a cut portion extending along a secant.
- the first receiving element (2) comprises a sidewall (12), which is arranged on the bottom wall (6) of the package body (3).
- This sidewall (12) and the sidewall (5) of the package body (3) define a cavity, which complies with the shape of the foot portion (303) of the replacement cap (300). In the present case of Figs. 6 to 8, this cavity and the foot portion (303) of the replacement cap (300) are shaped essentially circularly.
- the bearing surface (311) of the replacement cap (300) sits therefore on the bottom wall (6) of the package body (3), such that the replacement cap (300) is arranged in the package (1), such that an opening (309) of the replacement cap (300) is oriented along a vertical axis (Z) of the package body (3).
- An opening area (309a) of the replacement cap (300) is oriented parallel to the bottom wall (6) of the package body (3).
- the height (13) of the sidewall (12) along the vertical axis (Z) is essentially the height (310) of the replacement cap (300) at its outer edge.
- a use of the system (200) is displayed.
- the use comprises preferably removing the closure element from the package body (3).
- the pre-fillable syringe (100) is then retrieved from the package (1).
- the tip cap (103) is removed.
- the dosage of the pre-fillable syringe is set.
- the replacement cap (300) is mounted on the pre-fillable syringe (100).
- the syringe tip (102) is placed in the replacement cap (300) which is arranged in the package (1).
- the syringe tip (102) is let through the opening (309) of the replacement cap (300) and the opening (304) of the inner cap (301).
- the inner cap (301) is attached to the syringe tip (102) and the ring (305) or the struts (306) abut on the syringe barrel (101).
- the replacement cap (300) is still inside the package (1). Since the opening (309) of the replacement cap (300) is oriented along the vertical axis (Z) of the package body (3), the syringe tip (102) may easily be introduced into the replacement cap (300). The handling of the syringe (100) is therefore possible using only one hand. It is not necessary to put the pre-fillable syringe (100) down to obtain or align the replacement cap (300) relative to the pre-fillable syringe (100). The pre-fillable syringe (100) with the replacement cap (300) attached to it may then be retrieved from the package (1).
- the pre-fillable syringe (100) may preferably be placed in an upright position on a support surface (400).
- a foot portion (303) of the replacement cap (300) is suitable to provide a stable upright positioning of the pre-fillable syringe (100) with the replacement cap (300) on the support surface (400), wherein a bearing area (311) of a foot portion (303) of the replacement cap (300) contacts the support surface (400).
- Such a system (200) has the advantage that a package (1) is presented to the user which comprises the pre-fillable syringe (100) to use and a suitable replacement cap (300).
- the replacement cap (300) is already available to the user and does not need to be obtained otherwise. Further, the replacement cap (300) does not need to be retrieved from an additional package.
- the invention is also directed to the system herein disclosed, wherein the syringe is pre-filled with a ready-to-use pharmaceutical formulation.
- the pharmaceutical formulation is in form of solution or emulsion and comprises one or more active ingredients suitable for oral, intramuscular or intravenous administration. More advantageously, the formulation is an aqueous solution or a hydroalcoholic solution.
- the pharmaceutical formulation is an aqueous solution or a hydroalcoholic solution comprising buprenorphine, for an efficacious treatment by sublingual and/or buccal administration of patients affected by opiate withdrawal syndrome (OWS), more preferably neonates affected by neonatal OWS.
- OWS opiate withdrawal syndrome
- the buprenorphine formulation in form of aqueous solution comprises:
- a buffering agent in an amount to provide a pH of 5.0-7.0.
- Buprenorphine shall be utilized as a base or in the form of a pharmaceutically acceptable salt formed with an inorganic or organic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, acetic acid, glycolic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, malic acid, mandelic acid, tartaric acid, citric acid, ascorbic acid, palmitic acid, maleic acid, hydroxymaleic acid, benzoic acid, hydroxybenzoic acid, phenylacetic acid, cinnamic acid, salicylic acid, methanesulfonic acid, benzenesulfonic acid and toluenesulfonic acid.
- an inorganic or organic acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, acetic acid, glycolic acid, lactic acid, pyruvic
- buprenorphine is present as the hydrochloride salt.
- the concentration of buprenorphine, expressed as free base shall be comprised between 0.005 and 0.02% w/v, preferably between 0.006 and 0.01% w/v, expressed as free base.
- the concentration of buprenorphine hydrochloride is 0.0075% w/v, expressed as free base.
- the concentration of the thickening agent shall be comprised between 0.5% and 10%, w/v, preferably between 0.6%and 8.0% w/v.
- the type and amount of the thickening agent shall be properly selected to achieve an adequate viscosity to retain the formulation as much as possible under the tongue of the patient, to minimize the absorption through the gastrointestinal tract.
- the viscosity should be not too high to retard the release of the active ingredient from the matrix and hence, its local absorption.
- the concentration of the thickening agent may be between 1.0 and 6.0% w/v.
- said concentration is 1.0% w/v, or 1.5% w/v, or 2.0% w/v, or 6.0% w/v.
- the thickening agent may be selected from water-soluble polysaccharides such as alginates, carrageenans, pectin, water-soluble derivatives of cellulose: alkylcelluloses hydroxyalkylcelluloses and hydroxyalkylalkylcelluloses, such as methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxyethylmethylcellulose, hydroxypropylmethylcellulose, hydroxybutylmethylcellulose, cellulose esters and hydroxyalkylcellulose esters such as cellulose acetate phthalate (CAP), hydroxypropylmethylcellulose (HPMC); carboxyalkylcelluloses, carboxyalkylalkylcelluloses, carboxyalkylcellulose esters such as carboxymethylcellulose and their alkali metal salts; water-soluble synthetic polymers such as polyacrylic acids and polyacrylic acid esters, polymethacrylic acids and polymethacrylic acid esters, polyvinylacetates, polyvinylalcohols, polyvinyla
- the thickening agent is a water-soluble cellulose derivative selected from group consisting of hydroxyethylcellulose (HEC) or an alkali metal salt of carboxymethylcellulose (CMC) such as the sodium salt.
- HEC hydroxyethylcellulose
- CMC carboxymethylcellulose
- the thickening agents belonging to said classes may provide the suitable viscosity, while with other agents of the class of gums, such as xanthan gum, the viscosity of the formulation turned out to be too high.
- the viscosity of the formulation at 25 ⁇ 2°C shall be comprised between 500 and 2300 mPas (1 mPas corresponds to 1 centipoise), preferably between 700 and 2100 mPas
- the viscosity may be determined by any known method, for example using a rheometer.
- the pH of the formulation of the invention may be comprised between 5.0 and 7.0, more advantageously between 5.2 and 6.8, preferably between 5.5 and 6.5.
- preferred formulations When a water soluble cellulose derivative is used, preferred formulations have a pH between 5.5 and 6.5 and an amount of thickening agent comprised between 1.0% and 2.0% w/v, even more preferably of 1.5% w/v.
- the preferred thickening agent of this class may be hydroxy ethylcellulose. Said excipient is commercially available as Natrosol 250 HXTM.
- Any buffering agent able of providing the pH maybe used, for example phosphate or citrate buffers as sodium or potassium salts.
- phosphate or citrate buffers as sodium or potassium salts.
- the skilled person in the art shall determine the proper amount.
- anhydrous citric acid and sodium citrate anhydrous is used as buffering agent.
- Said formulation may also contain other excipients such as flavoring agents and/or sweeteners.
- Flavoring agents may be chosen from natural and synthetic flavoring liquids.
- An illustrative list of such agents includes volatile oils, synthetic flavor oils, flavoring aromatics, oils, liquids, oleoresins or extracts derived from plants, leaves, flowers, fruits, stems and combinations thereof.
- a representative list of examples includes mint oils, cocoa, and citrus oils such as lemon, orange, grape, lime and grapefruit and fruit essences including apple, pear, peach, grape, strawberry, raspberry, cherry, plum, pineapple, apricot or other fruit flavors.
- aldehydes and esters such as benzaldehyde (cherry, almond), citral i.e., alpha-citral (lemon, lime), neral, i.e., beta-citral (lemon, lime), decanal (orange, lemon), aldehyde C-8 (citrus fruits), aldehyde C-9 (citrus fruits), aldehyde C-12 (citrus fruits), tolyl aldehyde (cherry, almond), 2,6-dimethyloctanol (green fruit), and 2-dodecenal (citrus, mandarin), combinations thereof and the like.
- aldehydes and esters such as benzaldehyde (cherry, almond), citral i.e., alpha-citral (lemon, lime), neral, i.e., beta-citral (lemon, lime), decanal (orange, lemon), aldehyde C-8 (citrus fruits), al
- the sweeteners may be chosen from the following non-limiting list: glucose (com syrup), dextrose, invert sugar, fructose, and combinations thereof; saccharin and its various salts such as the sodium salt; dipeptide sweeteners such as aspartame; dihydrochalcone compounds, glycyrrhizin; Stevia rebaudiana (Stevioside); chloro derivatives of sucrose such as sucralose; sugar alcohols such as sorbitol, mannitol, xylitol, and the like.
- hydrogenated starch hydrolysates and the synthetic sweetener 3,6- dihydro-6-methyl-l-l-l, 2, 3-oxathiazin-4-one-2, 2-dioxide, particularly the potassium salt (acesulfame-K), and sodium and calcium salts thereof.
- Other sweeteners may also be used.
- the skilled person in art shall select the sweetener and/or flavoring agent among those considered safe for neonatal administration.
- Said formulation may also contain permeation enhancers such as propylene glycol, and polyoxyl hydrogenated castor oil derivatives, for example polyoxyl 40 hydrogenated castor oil (commercially available as Kolliphor RH 40TM).
- permeation enhancers such as propylene glycol
- polyoxyl hydrogenated castor oil derivatives for example polyoxyl 40 hydrogenated castor oil (commercially available as Kolliphor RH 40TM).
- the formulation has the following composition: 0.05-0.01% w/v buprenorphine hydrochloride expressed as a base, 1.5% w/v hydroxyethylcellulose, 0.12% w/v anhydrous citric acid, 1.13% w/v sodium citrate anhydrous, water for injection, and its pH is of 6.0 ⁇ 0.3.
- the formulation may have the following composition: 0.05-0.01% w/v buprenorphine hydrochloride expressed as a base, 6.0% w/v sodium carboxymethylcellulose, 0.12% w/v anhydrous citric acid, 1.13% w/v sodium citrate anhydrous, water for injection, and its pH is of 6.0 ⁇ 0.3.
- the pharmaceutical formulations can be prepared according to known methods.
- the pharmaceutical formulation is sterile and pre-filling is carried out under aseptic conditions is carried out according to methods known in the art.
- the pharmaceutical formulation can be in form of a dry powder to be dissolved extemporaneously before use.
- the invention is also directed to a kit comprising the system herein disclosed together with a pharmaceutical formulation in form of either ready-to-use aqueous solution or powder to be reconstituted in a suitable vehicle, and instructions to administer said pharmaceutical formulation.
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Environmental & Geological Engineering (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20714881.8A EP3938010A1 (en) | 2019-03-15 | 2020-03-11 | System comprising a pre-fillable syringe and a package for the pre-fillable syringe |
CA3130030A CA3130030A1 (en) | 2019-03-15 | 2020-03-11 | System comprising a pre-fillable syringe and a package for the pre-fillable syringe |
JP2021552171A JP7558959B2 (en) | 2019-03-15 | 2020-03-11 | System with prefillable syringe and package for prefillable syringe |
MX2021010362A MX2021010362A (en) | 2019-03-15 | 2020-03-11 | System comprising a pre-fillable syringe and a package for the pre-fillable syringe. |
BR112021015970-3A BR112021015970A2 (en) | 2019-03-15 | 2020-03-11 | SYSTEM COMPRISING A PRE-LOADING SYRINGE AND A PACKAGE FOR THE PRE-LOADING SYRINGE |
KR1020217029582A KR20210141501A (en) | 2019-03-15 | 2020-03-11 | A system comprising a pre-fillable syringe and a package for the pre-fillable syringe. |
AU2020244071A AU2020244071A1 (en) | 2019-03-15 | 2020-03-11 | System comprising a pre-fillable syringe and a package for the pre-fillable syringe |
CN202080020984.3A CN113573752A (en) | 2019-03-15 | 2020-03-11 | System comprising a prefillable syringe and a package for a prefillable syringe |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19163093 | 2019-03-15 | ||
EP19163093.8 | 2019-03-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020187660A1 true WO2020187660A1 (en) | 2020-09-24 |
Family
ID=65817887
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2020/056480 WO2020187660A1 (en) | 2019-03-15 | 2020-03-11 | System comprising a pre-fillable syringe and a package for the pre-fillable syringe |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP3938010A1 (en) |
JP (1) | JP7558959B2 (en) |
KR (1) | KR20210141501A (en) |
CN (1) | CN113573752A (en) |
AU (1) | AU2020244071A1 (en) |
BR (1) | BR112021015970A2 (en) |
CA (1) | CA3130030A1 (en) |
MA (1) | MA55294A (en) |
MX (1) | MX2021010362A (en) |
WO (1) | WO2020187660A1 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444310A (en) * | 1982-07-26 | 1984-04-24 | Becton, Dickinson And Company | Segmented multi-product package assembly |
WO1997010014A1 (en) * | 1995-09-13 | 1997-03-20 | Needle Technology (Aust) Limited | Needle housing |
WO2014045336A1 (en) * | 2012-09-18 | 2014-03-27 | テルモ株式会社 | Syringe packaging container |
EP3095476A1 (en) * | 2014-01-16 | 2016-11-23 | Terumo Kabushiki Kaisha | Syringe for injecting drug solution into upper skin layer |
WO2018038078A1 (en) | 2016-08-23 | 2018-03-01 | テルモ株式会社 | Medical equipment package |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI737742B (en) * | 2016-06-22 | 2021-09-01 | 德商梅茲製藥有限兩合公司 | Botulinum toxin prefilled syringe system, kit having the same and use thereof |
-
2020
- 2020-03-11 MA MA055294A patent/MA55294A/en unknown
- 2020-03-11 BR BR112021015970-3A patent/BR112021015970A2/en unknown
- 2020-03-11 CA CA3130030A patent/CA3130030A1/en active Pending
- 2020-03-11 EP EP20714881.8A patent/EP3938010A1/en active Pending
- 2020-03-11 JP JP2021552171A patent/JP7558959B2/en active Active
- 2020-03-11 MX MX2021010362A patent/MX2021010362A/en unknown
- 2020-03-11 CN CN202080020984.3A patent/CN113573752A/en active Pending
- 2020-03-11 AU AU2020244071A patent/AU2020244071A1/en active Pending
- 2020-03-11 WO PCT/EP2020/056480 patent/WO2020187660A1/en active Application Filing
- 2020-03-11 KR KR1020217029582A patent/KR20210141501A/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444310A (en) * | 1982-07-26 | 1984-04-24 | Becton, Dickinson And Company | Segmented multi-product package assembly |
WO1997010014A1 (en) * | 1995-09-13 | 1997-03-20 | Needle Technology (Aust) Limited | Needle housing |
WO2014045336A1 (en) * | 2012-09-18 | 2014-03-27 | テルモ株式会社 | Syringe packaging container |
EP3095476A1 (en) * | 2014-01-16 | 2016-11-23 | Terumo Kabushiki Kaisha | Syringe for injecting drug solution into upper skin layer |
WO2018038078A1 (en) | 2016-08-23 | 2018-03-01 | テルモ株式会社 | Medical equipment package |
Also Published As
Publication number | Publication date |
---|---|
MA55294A (en) | 2022-01-26 |
AU2020244071A1 (en) | 2021-09-02 |
KR20210141501A (en) | 2021-11-23 |
JP7558959B2 (en) | 2024-10-01 |
EP3938010A1 (en) | 2022-01-19 |
CN113573752A (en) | 2021-10-29 |
MX2021010362A (en) | 2021-09-30 |
CA3130030A1 (en) | 2020-09-24 |
BR112021015970A2 (en) | 2021-10-05 |
JP2022523408A (en) | 2022-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11369733B2 (en) | System comprising a pre-fillable syringe and a package for the pre-fillable syringe | |
BR112019027508A2 (en) | nasal dosage forms of dihydroergotamine | |
TW201143758A (en) | Syringe filter cap and method of using the same for administration of medication dosage | |
CN113613645B (en) | Transmucosal therapeutic system containing agomelatine | |
US11351299B2 (en) | System comprising a pre-fillable syringe and a package for the pre-fillable syringe | |
CA3202161A1 (en) | Liquid apixaban formulation in small dose volume | |
JP4588281B2 (en) | Oxcarbazepine-containing suspension | |
Niu et al. | FDA perspective on peptide formulation and stability issues | |
JP7558959B2 (en) | System with prefillable syringe and package for prefillable syringe | |
RU2811660C2 (en) | System containing pre-filled syringe and packaging for pre-filled syringe | |
US20200237650A1 (en) | Pharmaceutical formulations comprising opioid receptor agonist as active ingredients, methods of manufacture and therapeutic uses thereof | |
US20160030723A1 (en) | Multi-Chamber Anesthetic Delivery System | |
CN113597303A (en) | Transmucosal therapeutic system containing agomelatine | |
Jeong et al. | Fast disintegrating tablets | |
RU2795099C2 (en) | Pharmaceutical compositions containing an opioid receptor agonist as active ingredient, methods of their production and their therapeutic use | |
AU2004203644B2 (en) | Pharmaceutical compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20714881 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3130030 Country of ref document: CA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112021015970 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2021552171 Country of ref document: JP Kind code of ref document: A Ref document number: 2020244071 Country of ref document: AU Date of ref document: 20200311 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 112021015970 Country of ref document: BR Kind code of ref document: A2 Effective date: 20210812 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2020714881 Country of ref document: EP |